Valerio Therapeutics
Research Valerio Therapeutics (ALVIO) on Bullrun: market cap EUR 424.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALVIO
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 424.53M
- Financial periodFY2025
- RevenueEUR 2.57M
- Revenue growth43.5%
- Net income-EUR 4.90M
- Free cash flowEUR 521.00K
- Gross margin67.1%
Valuation Snapshot
latest market cap is EUR 424.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 2.57M | -EUR 4.90M | EUR 521.00K | 67.1% | n/a | EUR 1.05M | EUR 7.61M | EUR 2.08M |
| FY2024 | EUR 1.79M | -EUR 23.92M | -EUR 8.69M | 71.4% | n/a | EUR 1.18M | EUR 13.44M | -EUR 8.93M |
| FY2023 | EUR 1.80M | -EUR 20.34M | -EUR 17.57M | 70.4% | -0.15 | EUR 6.82M | EUR 9.00M | EUR 14.81M |
| FY2022 | EUR 1.44M | -EUR 19.56M | -EUR 9.93M | 64.4% | -0.18 | EUR 14.59M | EUR 10.09M | EUR 22.27M |
| FY2021 | n/a | n/a | n/a | n/a | -0.07 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 424.53M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody drug conjugates, and chimeric antigen receptors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Valerio Therapeutics's market cap?
Valerio Therapeutics's market capitalization is EUR 424.53M.
What does Valerio Therapeutics do?
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody drug conjugates, and chimeric antigen receptors.